RBC Capital Comments on Biogen (BIIB) and Tecfidera PML Case; Analyst Maintains Outperform Rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Baird Upgrades Biogen (BIIB) to Outperform
October 22, 2014 12:45 PM EDTBaird upgraded Biogen (NASDAQ: BIIB) from Neutral to Outperform with a price target of $382.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $326.77 yesterday.
... MoreBiogen Idec (BIIB) Says Tecfidera Patient Who Died had Low White Blood Cell Counts
October 22, 2014 11:52 AM EDTBiogen Idec Inc. (BIIB) is seeing some unnecessary weakness Wednesday following Q3 results and the company's conference call.
Earlier, the WSJ cited the company as saying it confirmed a... More
Biogen (BIIB): Deutsche Bank Comments on Recent Weakness And Compares it to Celgene (CELG)
October 22, 2014 10:52 AM EDTDeutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $430. Analyst Robyn Karnauskas commented on recent weakness and compared the stock to Celgene (NASDAQ: CELG). Overall, she is positive on both stocks.
"Biogen is trading weak post earnings due to 1) slower sequential revenue growth and 2) One PML case with Tecfidera disclosed on todays call. While we note that there is a good risk/reward... More
Biogen Idec (BIIB) Tops Q3 EPS by 31c; Boosts FY14 EPS Outlook
October 22, 2014 7:06 AM EDTBiogen Idec (NASDAQ: BIIB) reported Q3 EPS of $3.80, $0.31 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.5 billion versus the consensus estimate of $2.48 billion.
The third quarter was a period of significant achievement as we continued to make progress against our... More
